Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2000

01-06-2000

Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma

Authors: Qi-Feng Yang, Takeo Sakurai, Goro Yoshimura, Liang Shan, Takaomi Suzuma, Takeshi Tamaki, Teiji Umemura, Yozo Kokawa, Yasushi Nakamura, Misa Nakamura, Weihua Tang, Hirotoshi Utsunomiya, Ichiro Mori, Kennichi Kakudo

Published in: Breast Cancer Research and Treatment | Issue 3/2000

Login to get access
Metadata
Title
Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma
Authors
Qi-Feng Yang
Takeo Sakurai
Goro Yoshimura
Liang Shan
Takaomi Suzuma
Takeshi Tamaki
Teiji Umemura
Yozo Kokawa
Yasushi Nakamura
Misa Nakamura
Weihua Tang
Hirotoshi Utsunomiya
Ichiro Mori
Kennichi Kakudo
Publication date
01-06-2000
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2000
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006474307180

Other articles of this Issue 3/2000

Breast Cancer Research and Treatment 3/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine